



Result of AGM

December 15, 2023
RNS Number : 0572X
Renalytix PLC
15 December 2023

Renalytix plc ("Renalytix" or the "Company")

Result of AGM

LONDON and SALT LAKE, 15 December 2023 - Renalytix (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled *in vitro* diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that at the Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed.

The results of the AGM are detailed below:

	For	% voted in favour	Against	% voted against	Withheld
Ordinary resolutions					
1 Accept Financial Statements and Statutory Reports	40,118,702	99.94%	24,743	0.06%	67,418
2 Approve Remuneration Report	39,959,034	99.44%	226,856	0.56%	24,973
3 Re-elect Cathy Coste	39,058,428	97.29%	1,086,363	2.71%	66,072
4 Withdrawn	-	-	-	-	-
5 Reappoint EY	39,266,710	97.73%	910,387	2.27%	33,766
6 Reappoint PKF Littlejohn LLP as Auditors	40,142,582	99.91%	37,614	0.09%	30,667
7 Authorise Board to Fix Remuneration of Auditors	40,105,519	99.81%	77,729	0.19%	27,615
8 Authorise Issue of Equity	38,484,392	95.78%	1,697,234	4.22%	29,237
Special resolutions					
9 Authorise Issue of Equity without Pre-emptive Rights	38,467,804	95.74%	1,710,946	4.26%	32,113
10 Authorise Market Purchase of Ordinary Shares	39,597,340	99.87%	51,284	0.13%	562,239
11 Adoption of new articles	40,059,859	99.74%	104,681	0.26%	46,323

For further information, please contact:

Renalytix plc
James McCullough, CEO

www.renalytix.com
Via Walbrook PR

Stifel (Nominated Adviser, Joint Broker)

Alex Price / Nicholas Moore / Nick Harland / Samira Essebiyea

Tel: 020 7710 7600

Investec Bank plc (Joint Broker)

Gary Clarence / Shalin Bhamra

Tel: 020 7597 4000

Walbrook PR Limited

Paul McManus / Alice Woodings / Charlotte Edgar

Tel: 020 7933 8780 or renalytix@walbrookpr.com

Mob: 07980 541 893 / 07407 804 654 / 07884 664

686

About Renalytix

Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis™ for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D and early CKD (stages 1-3). We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

RAGBIBDDSBBDGXU